Clinical outcome for transplant recipients at 5 years from time of transplantation
. | Allograft . | . | . | Autograft . | . | . | Overall . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | ITD- . | ITD+ . | OR (95% CIs) . | ITD- . | ITD+ . | OR (95% CIs) . | OR (95% CIs) . | Het P* . | |||||
| Patients | 135 | 35 | — | 104 | 37 | — | — | — | |||||
| TRM | 27% | 40% | 1.48 (0.72-3.06) | 21% | 15% | 0.77 (0.29-2.08) | 1.18 (0.66-2.12) | .3 | |||||
| RR | 25% | 31% | 1.31 (0.56-3.06) | 35% | 56% | 2.39 (1.24-4.63) | 1.91 (1.13-3.21) | .3 | |||||
| DFS | 55% | 41% | 1.41 (0.82-2.44) | 51% | 38% | 1.69 (0.98-2.93) | 1.54 (1.05-2.28) | .6 | |||||
| OS | 58% | 44% | 1.44 (0.81-2.54) | 54% | 43% | 1.57 (0.89-2.77) | 1.51 (1.01-2.25) | .8 | |||||
. | Allograft . | . | . | Autograft . | . | . | Overall . | . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | ITD- . | ITD+ . | OR (95% CIs) . | ITD- . | ITD+ . | OR (95% CIs) . | OR (95% CIs) . | Het P* . | |||||
| Patients | 135 | 35 | — | 104 | 37 | — | — | — | |||||
| TRM | 27% | 40% | 1.48 (0.72-3.06) | 21% | 15% | 0.77 (0.29-2.08) | 1.18 (0.66-2.12) | .3 | |||||
| RR | 25% | 31% | 1.31 (0.56-3.06) | 35% | 56% | 2.39 (1.24-4.63) | 1.91 (1.13-3.21) | .3 | |||||
| DFS | 55% | 41% | 1.41 (0.82-2.44) | 51% | 38% | 1.69 (0.98-2.93) | 1.54 (1.05-2.28) | .6 | |||||
| OS | 58% | 44% | 1.44 (0.81-2.54) | 54% | 43% | 1.57 (0.89-2.77) | 1.51 (1.01-2.25) | .8 | |||||
OR indicates odds ratio; CIs, confidence intervals; TRM, treatment-related mortality; RR, relapse risk; DFS, disease-free survival; OS, overall survival; —, not applicable.
Heterogeneity P values (Het P) are for the interaction between type of transplant and FLT3/ITD status